About: The Use of Non‐invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID‐19: A Theoretical Hypothesis and Early Clinical Experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Use of Non‐invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID‐19: A Theoretical Hypothesis and Early Clinical Experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Use of Non‐invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID‐19: A Theoretical Hypothesis and Early Clinical Experience
Creator	Levy, Robert Blake, Justyna Giannakopoulos, Georgios Liebler, Eric Staats, Peter
Source	Medline; PMC; WHO
abstract	OBJECTIVES: Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a pandemic with no specific therapeutic agents and substantial mortality, and finding new treatments is critical. Most cases are mild, but a significant minority of patients develop moderate to severe respiratory symptoms, with the most severe cases requiring intensive care and/or ventilator support. This respiratory compromise appears to be due to a hyperimmune reaction, often called a cytokine storm. Vagus nerve stimulation has been demonstrated to block production of cytokines in sepsis and other medical conditions. We hypothesize that non‐invasive vagus nerve stimulation (nVNS) might provide clinical benefits in patients with respiratory symptoms similar to those associated with COVID‐19. MATERIALS AND METHODS: Information on two case reports was obtained via email correspondence and phone interviews with the patients. RESULTS: Both patients reported clinically meaningful benefits from nVNS therapy. In case 1, the patient used nVNS to expedite symptomatic recovery at home after hospital discharge and was able to discontinue use of opioid and cough suppressant medications. In case 2, the patient experienced immediate and consistent relief from symptoms of chest tightness and shortness of breath, as well as an improved ability to clear his lungs. CONCLUSIONS: Preliminary observations and a strong scientific foundation suggest that nVNS might provide clinical benefits in patients with COVID‐19 via multiple mechanisms.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.1111/ner.13172
bibo:pmid	32342609
has license	cc-by-nc-nd
sha1sum (hex)	7b71dc4e3d387aa46621cad25094c59fd36337d1
schema:url	https://doi.org/10.1111/ner.13172
resource representing a document's title	The Use of Non‐invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID‐19: A Theoretical Hypothesis and Early Clinical Experience
has PubMed Central identifier	PMC7267613
has PubMed identifier	32342609
schema:publication	Neuromodulation
resource representing a document's body	covid:7b71dc4e3d387aa46621cad25094c59fd36337d1#body_text
is schema:about of	named entity 'substantial' named entity 'support' named entity 'demonstrated' named entity 'symptoms' named entity 'Non-invasive' named entity 'With' named entity 'Neuromodulation' named entity 'Use' named entity 'SUPPORT' named entity 'TREATMENTS' named entity 'THERAPEUTIC AGENTS' named entity 'CASES' named entity 'CORONAVIRUS DISEASE 2019' named entity 'BUT' named entity 'SIMILAR' named entity 'CLINICAL EXPERIENCE' named entity 'TREAT' named entity 'INTERFACE' named entity 'NEUROMODULATION' named entity 'symptoms' named entity 'respiratory' named entity 'cytokines' named entity 'non-invasive' named entity 'vagus nerve stimulation' named entity 'bronchioles' named entity 'clinical trials' named entity 'IP-10' named entity 'IL-6' named entity 'treatment modality' named entity 'March 25' named entity 'vagus nerve stimulation' named entity 'patients' named entity 'ventilator' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'Nerve' named entity 'Stimulation' named entity 'COVID-19' named entity 'non-invasive' named entity 'intensive care' named entity 'respiratory symptoms' named entity 'COVID-19' named entity 'VNS' named entity 'neuromodulation' named entity 'asthma' named entity 'fatigue' named entity 'April 2' named entity 'type 2 diabetes mellitus' named entity 'COVID' named entity 'FEV' named entity 'symptom' named entity 'acetaminophen' named entity 'cytokines' named entity 'ARDS' named entity 'ramipril' named entity 'asthmatic reactions' named entity 'body aches' named entity 'Chest X-ray' named entity 'SARS-CoV-2' named entity 'open-label study' named entity 'acetaminophen' named entity 'asthma' named entity 'electrocardiogram' named entity 'coronavirus disease 2019' named entity 'coughing' named entity 'Vagus nerve stimulation' named entity 'shedding of the virus' named entity 'corticosteroids' named entity 'pantoprazole' named entity 'steroids' named entity 'chest tightness' named entity 'preventive treatment' named entity 'VNS' named entity 'inflammatory response' named entity 'respiratory symptoms' named entity 'visual analog scale' named entity 'inflammatory cytokine' named entity 'respiratory symptoms'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software